Clinical Trials - KALV

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT06467084Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or IIRECRUITINGPHASE32024-06-242027-08-312027-08-31
NCT05511922PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 TrialACTIVE_NOT_RECRUITINGPHASE32022-10-242026-06-302026-06-30
NCT05505916An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)ACTIVE_NOT_RECRUITINGPHASE32022-10-242026-06-302026-06-30
NCT05259917A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)COMPLETEDPHASE32022-02-222023-12-312023-12-31
NCT05055258A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or IITERMINATEDPHASE22021-09-272022-10-272022-10-27
NCT05118958Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) FormulationsCOMPLETEDPHASE12020-05-192020-12-012020-12-01
NCT04208412A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or IICOMPLETEDPHASE22019-07-022020-12-082020-12-08
NCT05178355A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy VolunteersCOMPLETEDPHASE12019-02-122019-06-212019-06-21
NCT03466099Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)COMPLETEDPHASE22018-02-162019-10-102019-10-10
NCT04349800A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy VolunteersCOMPLETEDPHASE12018-01-042018-09-102018-09-10
NCT02193113A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DMECOMPLETEDPHASE12014-07-182015-06-042015-06-04